What is OBSOLETE: Acquired amyloid myopathy?
Acquired amyloid myopathy is a rare condition in which abnormal proteins called amyloid build up in the muscles of the body. Unlike inherited forms of amyloidosis, this type is not passed down through families but develops later in life, often in connection with other conditions such as plasma cell disorders (like multiple myeloma or monoclonal gammopathy). The amyloid deposits damage muscle tissue, leading to progressive muscle weakness and sometimes muscle enlargement (pseudohypertrophy), which can make muscles look bigger even though they are getting weaker. Patients may notice difficulty climbing stairs, rising from a chair, lifting objects, or performing everyday tasks. Some people also experience muscle stiffness, fatigue, and difficulty swallowing if the throat muscles are affected. Note that this disease entry is marked as 'OBSOLETE' in Orphanet, meaning it may have been reclassified or merged into a broader category of amyloidosis-related muscle disease. The treatment landscape focuses on addressing the underlying cause of amyloid production, such as treating the plasma cell disorder, along with supportive care for muscle symptoms. There is no single cure, and management is tailored to each patient's situation. Early recognition is important because treating the underlying condition may slow or stop further amyloid buildup in the muscles.
Key symptoms:
Progressive muscle weaknessMuscle enlargement (pseudohypertrophy)Difficulty climbing stairsTrouble rising from a seated positionDifficulty lifting arms above the headMuscle stiffnessFatigueDifficulty swallowing (dysphagia)Muscle pain or tendernessReduced grip strengthShortness of breath with exertionUnintentional weight lossEnlarged tongue (macroglossia)
- Inheritance
- Sporadic
- Usually appears on its own, not inherited from a parent
- Age of Onset
- Adult
- Begins in adulthood (age 18 or older)
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for OBSOLETE: Acquired amyloid myopathy.
View clinical trials →Clinical Trials
View all trials with filters →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
No actively recruiting trials found for OBSOLETE: Acquired amyloid myopathy at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for OBSOLETE: Acquired amyloid myopathy.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to OBSOLETE: Acquired amyloid myopathy.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Acquired amyloid myopathy.
Start the conversation →Latest news about OBSOLETE: Acquired amyloid myopathy
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for OBSOLETE: Acquired amyloid myopathy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What type of amyloid is causing my muscle problems, and what is the underlying cause?,What treatment options are available for my specific situation?,How will we monitor whether the treatment is working?,Are my heart or other organs also affected by amyloid?,What can I do to maintain my muscle strength and function?,Should I be referred to any additional specialists?,Are there any clinical trials I might be eligible for?
Common questions about OBSOLETE: Acquired amyloid myopathy
What is OBSOLETE: Acquired amyloid myopathy?
Acquired amyloid myopathy is a rare condition in which abnormal proteins called amyloid build up in the muscles of the body. Unlike inherited forms of amyloidosis, this type is not passed down through families but develops later in life, often in connection with other conditions such as plasma cell disorders (like multiple myeloma or monoclonal gammopathy). The amyloid deposits damage muscle tissue, leading to progressive muscle weakness and sometimes muscle enlargement (pseudohypertrophy), which can make muscles look bigger even though they are getting weaker. Patients may notice difficulty c
How is OBSOLETE: Acquired amyloid myopathy inherited?
OBSOLETE: Acquired amyloid myopathy follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Acquired amyloid myopathy typically begin?
Typical onset of OBSOLETE: Acquired amyloid myopathy is adult. Age of onset can vary across affected individuals.
Frequently asked questions about OBSOLETE: Acquired amyloid myopathy
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is OBSOLETE: Acquired amyloid myopathy?
OBSOLETE: Acquired amyloid myopathy is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:207006). It is typically inherited as sporadic. Age of onset is generally adult. For verified primary sources, see the UniteRare OBSOLETE: Acquired amyloid myopathy page.
How is OBSOLETE: Acquired amyloid myopathy inherited?
OBSOLETE: Acquired amyloid myopathy follows sporadic inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for OBSOLETE: Acquired amyloid myopathy?
Approved treatments for OBSOLETE: Acquired amyloid myopathy are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials for OBSOLETE: Acquired amyloid myopathy?
Active clinical trials for OBSOLETE: Acquired amyloid myopathy are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.
How do I find a specialist for OBSOLETE: Acquired amyloid myopathy?
Verified OBSOLETE: Acquired amyloid myopathy specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full OBSOLETE: Acquired amyloid myopathy page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.